Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares rose 24.6% during mid-day trading on Wednesday . The stock traded as high as $1.14 and last traded at $1.06. Approximately 2,994,528 shares were traded during trading, an increase of 138,215% from the average daily volume of 2,165 shares. The stock had previously closed at $0.8506.
Graybug Vision Price Performance
The stock has a market capitalization of $1.67 million, a PE ratio of -0.61 and a beta of 1.20. The company has a 50 day moving average price of $0.73 and a 200-day moving average price of $2.13.
About Graybug Vision
Graybug Vision, Inc is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. The company’s proprietary Depot Technology Platform is designed to deliver sustained-release formulations of biologically active agents directly to the back of the eye, with the goal of reducing treatment burden and improving patient outcomes. Graybug’s lead product candidate, GB-102, is a long-acting formulation of sunitinib malate being investigated for the treatment of wet age-related macular degeneration (wet AMD).
Recommended Stories
- Five stocks we like better than Graybug Vision
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
